Page 27 - Mesenchymal Stem Cell-Derived Exosomes as an Emerging Paradigm for Regenerative Therapy and Nano-Medicine

W J S C World Journal of

Stem Cells

Submit a Manuscript: https://www.f6publishing.com World J Stem Cells 2020 March 26; 12(3): 178-187
DOI: 10.4252/wjsc.v12.i3.178 ISSN 1948-0210 (online)

REVIEW

Mesenchymal stem cell-derived extracellular vesicles as a new
therapeutic strategy for ocular diseases

Bo Yu, Xiao-Rong Li, Xiao-Min Zhang

ORCID number: Bo Yu Bo Yu, Xiao-Rong Li, Xiao-Min Zhang, Tianjin International Joint Research and Development
(0000-0003-1754-5798); Xiao-Rong Center of Ophthalmology and Vision Science, Tianjin Key Laboratory of Retinal Functions
Li (0000-0001-6855-7671); Xiao-Min and Diseases, Eye Institute and School of Optometry, Tianjin Medical University Eye
Zhang (0000-0003-4898-4152). Hospital, Tianjin 300384, China

Author contributions: All authors Corresponding author: Xiao-Min Zhang, MD, PhD, Chief Doctor, Professor, Tianjin
equally contributed to this International Joint Research and Development Center of Ophthalmology and Vision Science,
manuscript.
Tianjin Key Laboratory of Retinal Functions and Diseases, Eye Institute and School of
Optometry, Tianjin Medical University Eye Hospital, No. 251, Fukang Road, Tianjin 300384,
Supported by National Natural
Science Foundation of China, No. China. xzhang08@tmu.edu.cn
81800825, No. 81870651 and No.
81870675.
Conflict-of-interest statement: The Abstract
authors have no conflicts to
declare. Mesenchymal stem cells (MSCs) have attracted considerable attention for their
activity in the treatment of refractory visual disorders. Since MSCs were found to
Open-Access: This article is an possess the beneficial effects by secreting paracrine factors rather than direct
open-access article that was differentiation, MSC-derived extracellular vesicles (EVs) were widely studied in
selected by an in-house editor and various disease models. MSCs generate abundant EVs, which act as important
fully peer-reviewed by external mediators by exchanging protein and genetic information between MSCs and
reviewers. It is distributed in
accordance with the Creative target cells. It has been confirmed that MSC-derived EVs possess unique anti-
Commons Attribution inflammatory, anti-apoptotic, tissue repairing, neuroprotective, and
NonCommercial (CC BY-NC 4.0) immunomodulatory properties, similar to their parent cells. Upon intravitreal
license, which permits others to injection, MSC-derived EVs rapidly diffuse through the retina to alleviate retinal
distribute, remix, adapt, build injury or inflammation. Due to possible risks associated with MSC
upon this work non-commercially,
and license their derivative works transplantation, such as vitreous opacity and pathological proliferation, EVs
on different terms, provided the appear to be a better choice for intravitreal injection. Small size EVs can pass
original work is properly cited and through biological barriers easily and their contents can be modified genetically
the use is non-commercial. See: for optimal therapeutic effect. Hence, currently, they are also explored for the
http://creativecommons.org/licen possibility of serving as drug delivery vehicles. In the current review, we describe
ses/by-nc/4.0/
the characteristics of MSC-derived EVs briefly, comprehensively summarize their
Manuscript source: Invited biological functions in ocular diseases, and discuss their potential applications in
manuscript clinical settings.
Received: December 27, 2019
Key words: Mesenchymal stem cells; Extracellular vesicles; Exosomes; Ocular diseases;
Peer-review started: December 27,
2019 Drug delivery
First decision: February 20, 2020
Revised: February 22, 2020 ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Accepted: March 22, 2020
Article in press: March 22, 2020 Core tip: The therapeutic potential of Mesenchymal stem cell (MSC)-derived
Published online: March 26, 2020 extracellular vesicles (EVs) has been widely studied in various diseases. In the current

WJSC https://www.wjgnet.com 178 March 26, 2020 Volume 12 Issue 3